# US 2025/0012820 A1 · Multi-parameter metabolic vulnerability index evaluations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0012820 A1
- Document ID: US20250012820A1
- Status: Published application
- Kind: A1
- Application number: 18/890,018
- Filed: 2024-09-19
- Published: 2025-01-09
- Earliest claimed: 2017-09-07
- Assignees: LipoScience, Inc.
- Applicants: LipoScience, Inc.
- Inventors: James D. Otvos; Irina Y. Shalaurova
- Web page: https://patentgrep.com/patent/US20250012820A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- G01R 33/465: applied to biological material, e.g. in vitro testing
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/50: for simulation or modelling of medical disorders
- G16Z 99/00: Subject matter not provided for in other main groups of this subclass
- G01N 2800/32: Cardiovascular disorders
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16C 20/20: Identification of molecular entities, parts thereof or of chemical compositions
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16Z: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE

## Abstract

Disclosed are methods and systems to determine a subject's metabolic vulnerability index (MVX) score using at least one defined mathematical model of risk. The methods comprise evaluating various biomarkers to distinguish various health risks. In one embodiment, the method comprises evaluating biomarkers to determine a relative risk of premature all-cause mortality. The model may include NMR-derived measurements of GlycA, S-HDLP, branched chain amino acids (BCAAs), ketone bodies, total serum protein, and citrate in at least one biosample of the subject.

## Claims

### Claim 1

A method of determining the levels of markers associated with a subject's relative risk of premature death comprising:
obtaining a sample from the subject; and
measuring GlycA, at least one high density lipoprotein particle (HDLP) subclass, at least one branched chain amino acid (BCAA), and at least one ketone body (KetoneBody).

### Claim 2 (depends on 1)

The method of claim 1, wherein the measurement of the GlycA, the at least one HDLP subclass, the at least one BCAA, and the at least one ketone body are used to generate a metabolic vulnerability index (MVX) value.

### Claim 3 (depends on 1)

The method of claim 1, wherein the HDLP subclass is small HDLP (S-HDLP).

### Claim 4 (depends on 3)

The method of claim 3, wherein the MVX value is determined using the following model: MVX=A+β1*InGlycA+β2*InS-HDLP+β4*InBCAA+β5*InKetoneBody.

### Claim 5 (depends on 3)

The method of claim 3, wherein the MVX value is determined using the following model: MVX=A+β1*InGlycA+β2*InS-HDLP+β3*(InGlycA*InS-HDLP)+β4*InBCAA+β5*InKetoneBody.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, further comprising measuring at least one of citrate (Citrate) and serum protein (Protein).

### Claim 8 (depends on 7)

The method of claim 7, wherein the measuring of at least one of citrate and serum protein is performed in a subject deemed to be at high risk for CVD related death.

### Claim 9 (depends on 7)

The method of claim 7, wherein the MVX value is determined using the following model: MVX=A+β1*InGlycA+β2*InS-HDLP+β3*(InGlycA*InS-HDLP)+β4*InBCAA+β5*In KetoneBody+β6*InCitrate+β7*InProtein+β8*(InCitrate*InProtein).

### Claim 10 (depends on 1)

The method of claim 1, wherein the MVX value is defined as comprising an inflammation index (INFX) value and a metabolic malnutrition index (MMX) value.

### Claim 11 (depends on 10)

The method of claim 10, wherein the measurement of GlycA and the at least one HDLP subclass are used to generate an inflammation index (INFX) value.

### Claim 12 (depends on 10)

The method of claim 10, wherein the INFX value is determined using the following model: INFX=β1*InGlycA+β2*InS-HDLP+β3*(InGlycA*InS-HDLP).

### Claim 13 (depends on 10)

The method of claim 10, wherein the measurement of the at least one BCAA and the at least one ketone body, and optionally protein and citrate, are used to generate the metabolic malnutrition index (MMX) value.

### Claim 14 (depends on 10)

The method of claim 10, wherein the metabolic malnutrition index (MMX) value is defined as: MMX=β4*InBCAA+β5*InKetoneBody+β6*InCitrate+β7*InProtein+β8*(InCitrate*InProtein).

### Claim 15 (depends on 10)

The method of claim 10 wherein the metabolic malnutrition index (MMX) comprises a first metabolic malnutrition index MMX1 value and a second metabolic malnutrition index MMX2 value.

### Claim at position 16

16-22. (canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein the BCAA is at least one of leucine, isoleucine, or valine.

### Claim 24 (depends on 1)

The method of claim 1, wherein the ketone bodies are at least one of acetone, acetoacetate, or beta-hydroxybutyrate.

### Claim 25 (depends on 1)

The method of claim 1, wherein the measuring is performed by NMR.

### Claim 26

A system comprising:
an NMR spectrometer configured to acquire an NMR spectrum and/or spectra comprising at least one signal for GlycA, at least one signal for at least one high density lipoprotein particle (HDLP) subclass, at least one signal for at least one branched chain amino acid (BCAA), and at least one signal for at least one ketone body (KetoneBody); and
a processor to determine a metabolic vulnerability index (MVX) value based on the measured at least one signal for the GlycA, the at least one high density lipoprotein particle (HDLP) subclass, the at least one branched chain amino acid (BCAA), and the at least one ketone body (KetoneBody)
wherein the processor comprises or communicates with a memory.

### Claim 27 (depends on 26)

The system of claim 26, further comprising an NMR spectrometer configured to acquire an NMR spectrum and/or spectra comprising at least one signal for serum protein (Protein) and/or citrate (Citrate); and
a processor to determine a metabolic vulnerability index (MVX) value based on the measured at least one signal for the serum protein (Protein) and the citrate (Citrate).

### Claim 28

(canceled)

### Claim 29

A method of monitoring a patient comprising:
(a) obtaining a sample from the subject;
(b) measuring GlycA, at least one high density lipoprotein particle (HDLP) subclass, at least one branched chain amino acid (BCAA), and at least one ketone body (KetoneBody) and optionally at least one of citrate (Citrate) and serum protein (Protein) in the sample;
(c) determining a metabolic vulnerability index (MVX) value based on the measurements;
(d) repeating steps (a)-(c) at a later time point; and
(e) evaluating at least whether the MVX value has increased or decreased over time.

### Claim at position 24

30-31. (canceled)
